[Source: Phoenix Business Journal – by Angela Gonzales] – InNexus Biotechnology Inc. has completed a primate study it says confirms the effectinvess and safety of its treatment for non-Hodgkins lymphoma tumors.
The Toronto, Canadian company (TSX:IXS.V), whose business offices are based in Scottsdale, also scheduled a meeting with the U.S. Food and Drug Administration to discuss the design of a clinical study on humans.
For more information click here.